ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients
Received 17 October 2019
Accepted for publication 26 February 2020
Published 16 March 2020 Volume 2020:13 Pages 81—88
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Martin H. Bluth
Hyun Jeong Kim, 1,* Nga Thi Trinh, 1,* Yunjeong Choi, 1 Woorim Kim, 1 Kyung Hyun Min, 1 Sang Oh Kang, 1 Joo Hee Kim, 2 Hyoun-Ah Kim, 3 Ju-Yang Jung, 3 In Ah Choi, 4 Kyung Eun Lee 1
1College of Pharmacy, Chungbuk National University, Cheongju-si, Republic of Korea; 2College of Pharmacy, Ajou University, Suwon, Republic of Korea; 3Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea; 4Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea
*These authors contributed equally to this work
Correspondence: Kyung Eun Lee
College of Pharmacy, Chungbuk National University, 660-1 Yeonje-ri, Osong-eup, Heungdeok-gu, Cheongju-si 28160, Republic of Korea
Tel +82 43 261 3590
Fax +82 43 268 2732
Purpose: TNF-α is a transmembrane protein which requires cleavage by ADAM17 in order to act systemically. The activation of ADAM17 to generate soluble TNF‑α results in an increased inflammatory activity. We hypothesized that variants spanning the ADAM17 gene contribute towards the observed variation in patient response defined by the number of changes in TNF‑α inhibitors.
Patients and Methods: Seven single-nucleotide polymorphisms (SNPs) of ADAM17 in 63 patients with rheumatoid arthritis who received TNF-α inhibitors were analyzed: rs57467365, rs62117540, rs117645314, rs6432013, rs532704607, rs117179141, and rs12692386. Univariate and multivariate regression analysis were employed to investigate the independent predictable factors for changes in TNF-α inhibitors.
Results: ADAM17 rs117645314 and rs117179141 showed significant association with the number of changes in TNF-α inhibitors. Patients with GA in rs117645314 and AT in rs117179141 had significantly higher chance of two or more changes of TNF-α inhibitors than those with wild homozygous alleles. Multivariate analysis showed that rs117179141 explained 5.7% of the 23.8% variability in TNF-α inhibitor response.
Conclusion: This study showed that the number of changes in TNF-α inhibitor is associated with ADAM17 SNPs.
Keywords: rheumatoid arthritis, TNF-α inhibitor, ADAM17, single-nucleotide polymorphism
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]